Key result
Endothelial cells from visceral adipose tissue of obese subjects decreased adipocyte lipolytic activity and insulin sensitivity, which was partially rescued by anti-inflammatory angiopoietin-1.
Why the study?
Does Angiopoietin-1 improve adipocyte dysfunction induced by visceral adipose tissue endothelial cells in obesity?
Does Angiopoietin-1 improve adipocyte dysfunction induced by visceral adipose tissue endothelial cells in obesity?
Endothelial cells from visceral adipose tissue in obesity negatively impact adipocyte function, which can be partially rescued by the anti-inflammatory factor Angiopoietin-1.
VAT-ECs may drive adipocyte dysfunction in obesity; leaves open whether anti-inflammatory rescue translates clinically.
During obesity, chronic inflammation of human white adipose tissue (WAT) is associated with metabolic and vascular alterations. Endothelial cells from visceral WAT (VAT-ECs) exhibit a proinflammatory and senescent phenotype and could alter adipocyte functions. We aimed to determine the contribution of VAT-ECs to adipocyte dysfunction related to inflammation and to rescue these alterations by anti-inflammatory strategies. We developed an original three-dimensional setting allowing maintenance of unilocular adipocyte functions. Coculture experiments demonstrated that VAT-ECs provoked a decrease in the lipolytic activity, adipokine secretion, and insulin sensitivity of adipocytes from obese subjects, as well as an increased production of several inflammatory molecules. Interleukin (IL)-6 and IL-1β were identified as potential actors in these adipocyte alterations. The inflammatory burst was not observed in cocultured cells from lean subjects. Interestingly, pericytes, in functional interactions with ECs, exhibited a proinflammatory phenotype with diminished angiopoietin-1 (Ang-1) secretion in WAT from obese subjects. Using the anti-inflammatory Ang-1, we corrected some deleterious effects of WAT-ECs on adipocytes, improving lipolytic activity and insulin sensitivity and reducing the secretion of proinflammatory molecules. In conclusion, we identified a negative impact of VAT-ECs on adipocyte functions during human obesity. Therapeutic options targeting EC inflammation could prevent adipocyte alterations that contribute to obesity comorbidities.
No takes yet. Share an insight, caveat, or question.
Pellegrinelli et al. (2013) studied Obesity. Angiopoietin-1 vs. No Angiopoietin-1 was evaluated on Adipocyte functions (lipolytic activity, adipokine secretion, insulin sensitivity, and inflammatory molecule production). Endothelial cells from visceral adipose tissue of obese subjects decreased adipocyte lipolytic activity and insulin sensitivity, which was partially rescued by anti-inflammatory angiopoietin-1.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: